KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.4 billion.

  • Regeneron Pharmaceuticals' Income from Continuing Operations rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • Regeneron Pharmaceuticals' Income from Continuing Operations amounted to $4.4 billion in FY2024, which was up 11.61% from $4.0 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Income from Continuing Operations peaked at $8.1 billion during FY2021, and registered a low of $3.5 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Income from Continuing Operations value was $4.3 billion (recorded in 2022), while the average stood at $4.2 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Income from Continuing Operations skyrocketed by 129.86% in 2021 and then plummeted by 46.28% in 2022.
  • Regeneron Pharmaceuticals' Income from Continuing Operations (Yearly) stood at $3.5 billion in 2020, then surged by 129.86% to $8.1 billion in 2021, then crashed by 46.28% to $4.3 billion in 2022, then decreased by 8.87% to $4.0 billion in 2023, then increased by 11.61% to $4.4 billion in 2024.